155 related articles for article (PubMed ID: 37524151)
1. Safety pharmacology 2023 and implementation of the ICH E14/S7B Q&A guidance document.
Pugsley MK; Koshman YE; Foley CM; Winters BR; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2023; 123():107300. PubMed ID: 37524151
[TBL] [Abstract][Full Text] [Related]
2. Safety pharmacology methods and models in an evolving regulatory environment.
Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240
[TBL] [Abstract][Full Text] [Related]
3. Innovative approaches to cardiovascular safety pharmacology assessment.
Pugsley MK; Winters BR; Koshman YE; Authier S; Foley CM; Hayes ES; Curtis MJ
J Pharmacol Toxicol Methods; 2024 Jun; ():107533. PubMed ID: 38945308
[TBL] [Abstract][Full Text] [Related]
4. Innovation in safety pharmacology testing.
Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
[TBL] [Abstract][Full Text] [Related]
5. Methodological innovations expand the safety pharmacology horizon.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
[TBL] [Abstract][Full Text] [Related]
6. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
[TBL] [Abstract][Full Text] [Related]
7. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
8. Twenty years of safety pharmacology model validation and the wider implications of this to drug discovery.
Pugsley MK; Bekele B; Griessel H; de Korte T; Authier S; Grobler AF; Markgraf CG; Curtis MJ
J Pharmacol Toxicol Methods; 2020 Sep; 105():106912. PubMed ID: 32798702
[TBL] [Abstract][Full Text] [Related]
9. Safety pharmacology in 2014: new focus on non-cardiac methods and models.
Pugsley MK; Dalton JA; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2014; 70(2):170-4. PubMed ID: 25128820
[TBL] [Abstract][Full Text] [Related]
10. Methodology used in safety pharmacology: appraisal of the state-of-the-art, the regulatory issues and new directions.
Pugsley MK
J Pharmacol Toxicol Methods; 2005; 52(1):1-5. PubMed ID: 15982903
[TBL] [Abstract][Full Text] [Related]
11. The shifting landscape of safety pharmacology in 2015.
Pugsley MK; Authier S; Stonerook M; Curtis MJ
J Pharmacol Toxicol Methods; 2015; 75():5-9. PubMed ID: 26055120
[TBL] [Abstract][Full Text] [Related]
12. Methods in safety pharmacology in focus.
Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
[TBL] [Abstract][Full Text] [Related]
13. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.
Cavero I; Crumb W
Expert Opin Drug Saf; 2005 May; 4(3):509-30. PubMed ID: 15934857
[TBL] [Abstract][Full Text] [Related]
14. Safety pharmacology in 2022: Taking one small step for cardiovascular safety assay development but one giant leap for regulatory drug safety assessment.
Pugsley MK; Koshman YE; de Korte T; Authier S; Winters BR; Curtis MJ
J Pharmacol Toxicol Methods; 2022; 117():107206. PubMed ID: 35926772
[TBL] [Abstract][Full Text] [Related]
15. Reprint of "Safety pharmacology in 2014: New focus on non-cardiac methods and models".
Pugsley MK; Dalton JA; Authier S; Curtis MJ
J Pharmacol Toxicol Methods; 2014; 70(3):199-203. PubMed ID: 25467811
[TBL] [Abstract][Full Text] [Related]
16. The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment.
Abi-Gerges N; McMahon C; Vargas H; Sager P; Chui R; Stevens D; Davila J; Schaub JR; Wu JC; Del Rio C; Mathes C; Miller PE; Burns-Naas LA; Ghetti A
J Pharmacol Toxicol Methods; 2019; 98():106582. PubMed ID: 31077805
[TBL] [Abstract][Full Text] [Related]
17. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
[TBL] [Abstract][Full Text] [Related]
18. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
19. An overview of the safety pharmacology society strategic plan.
Pugsley MK; Authier S; Koerner JE; Redfern WS; Markgraf CG; Brabham T; Correll K; Soloviev MV; Botchway A; Engwall M; Traebert M; Valentin JP; Mow TJ; Greiter-Wilke A; Leishman DJ; Vargas HM
J Pharmacol Toxicol Methods; 2018; 93():35-45. PubMed ID: 29330132
[TBL] [Abstract][Full Text] [Related]
20. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
